Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2023
Historique:
pubmed: 7 2 2023
medline: 15 3 2023
entrez: 6 2 2023
Statut: ppublish

Résumé

Alzheimer's disease (AD) frequently co-occurs with other brain pathologies. Recent studies suggest there may be a mechanistic link between AD and small vessel cerebrovascular disease (CVD), as opposed to simply the overlap of two disorders. We investigated the cross-sectional relationship between white matter hyperintensity (WMH) volumes (markers of CVD) and cerebrospinal fluid (CSF) biomarkers of AD. WMH volumes were assessed globally and regionally (i.e., frontal, parietal, temporal, occipital, and limbic). CSF AD biomarkers (i.e., Aβ 40, Aβ 42, Aβ 42/Aβ 40 ratio, phosphorylated tau-181 [p-tau181], and total tau [t-tau]) were measured among 152 non-demented individuals (134 cognitively unimpaired and 18 with mild cognitive impairment (MCI)). Linear regression models showed that among all subjects, higher temporal WHM volumes were associated with AD biomarkers (higher levels of p-tau181, t-tau, and Aβ 40), particularly among APOE ɛ 4 carriers (independent of Aβ 42 levels). Higher vascular risk scores were associated with greater parietal and frontal WMH volumes (independent of CSF AD biomarker levels). Among subjects with MCI only, parietal WMH volumes were associated with a lower level of Aβ 42/Aβ 40. In addition, there was an association between higher global WMH volumes and higher CSF t-tau levels among younger participants versus older ones (∼<65 versus 65+ years), independent of Aβ 42/Aβ 40 and p-tau181. These findings suggest that although WMH are primarily related to systemic vascular risk and neurodegeneration (i.e., t-tau), AD-specific pathways may contribute to the formation of WMH in a regionally-specific manner, with neurofibrillary tangles (i.e., p-tau) playing a role in temporal WMHs and amyloid (i.e., Aβ 42/Aβ 40) in parietal WMHs.

Sections du résumé

BACKGROUND
Alzheimer's disease (AD) frequently co-occurs with other brain pathologies. Recent studies suggest there may be a mechanistic link between AD and small vessel cerebrovascular disease (CVD), as opposed to simply the overlap of two disorders.
OBJECTIVE
We investigated the cross-sectional relationship between white matter hyperintensity (WMH) volumes (markers of CVD) and cerebrospinal fluid (CSF) biomarkers of AD.
METHODS
WMH volumes were assessed globally and regionally (i.e., frontal, parietal, temporal, occipital, and limbic). CSF AD biomarkers (i.e., Aβ 40, Aβ 42, Aβ 42/Aβ 40 ratio, phosphorylated tau-181 [p-tau181], and total tau [t-tau]) were measured among 152 non-demented individuals (134 cognitively unimpaired and 18 with mild cognitive impairment (MCI)).
RESULTS
Linear regression models showed that among all subjects, higher temporal WHM volumes were associated with AD biomarkers (higher levels of p-tau181, t-tau, and Aβ 40), particularly among APOE ɛ 4 carriers (independent of Aβ 42 levels). Higher vascular risk scores were associated with greater parietal and frontal WMH volumes (independent of CSF AD biomarker levels). Among subjects with MCI only, parietal WMH volumes were associated with a lower level of Aβ 42/Aβ 40. In addition, there was an association between higher global WMH volumes and higher CSF t-tau levels among younger participants versus older ones (∼<65 versus 65+ years), independent of Aβ 42/Aβ 40 and p-tau181.
CONCLUSION
These findings suggest that although WMH are primarily related to systemic vascular risk and neurodegeneration (i.e., t-tau), AD-specific pathways may contribute to the formation of WMH in a regionally-specific manner, with neurofibrillary tangles (i.e., p-tau) playing a role in temporal WMHs and amyloid (i.e., Aβ 42/Aβ 40) in parietal WMHs.

Identifiants

pubmed: 36744337
pii: JAD220846
doi: 10.3233/JAD-220846
pmc: PMC10041440
doi:

Substances chimiques

Amyloid beta-Peptides 0
tau Proteins 0
Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-339

Subventions

Organisme : NIA NIH HHS
ID : P30 AG066507
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB031771
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG033655
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005146
Pays : United States

Références

Stroke. 1999 Mar;30(3):529-36
pubmed: 10066847
J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1271-1277
pubmed: 34344790
Science. 1993 Aug 13;261(5123):921-3
pubmed: 8346443
Neurology. 2012 Sep 25;79(13):1349-55
pubmed: 22972646
Neurology. 2020 Nov 10;95(19):e2622-e2634
pubmed: 32732300
Int J Cardiol Heart Vasc. 2018 May 14;19:63-69
pubmed: 29946567
Brain Commun. 2020 Aug 19;2(2):fcaa132
pubmed: 33215083
Alzheimers Res Ther. 2021 Oct 15;13(1):174
pubmed: 34654465
Stroke. 2011 Sep;42(9):2672-713
pubmed: 21778438
Alzheimers Res Ther. 2019 Sep 14;11(1):81
pubmed: 31521199
Alzheimers Res Ther. 2015 Jun 01;7(1):30
pubmed: 26034513
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Alzheimers Dement (Amst). 2021 May 01;13(1):e12182
pubmed: 33969174
Ann Neurol. 2016 Jun;79(6):929-39
pubmed: 27016429
Nature. 2020 May;581(7806):71-76
pubmed: 32376954
Nat Rev Neurosci. 2017 Jul;18(7):419-434
pubmed: 28515434
Neurology. 2018 Sep 4;91(10):e964-e975
pubmed: 30076276
Science. 2019 Jul 19;365(6450):
pubmed: 31221773
J Alzheimers Dis. 2021;83(1):155-162
pubmed: 34250938
JAMA Neurol. 2013 Apr;70(4):488-95
pubmed: 23400560
Neurobiol Aging. 2016 Dec;48:48-52
pubmed: 27639120
Acta Neuropathol. 2017 Sep;134(3):459-473
pubmed: 28638989
Alzheimers Dement (Amst). 2016 Apr 07;4:18-27
pubmed: 27489875
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Neurology. 2016 Feb 9;86(6):535-43
pubmed: 26747881
JAMA Neurol. 2014 Jul 1;71(7):855-62
pubmed: 24818585
Cereb Cortex. 2012 May;22(5):1038-51
pubmed: 21765181
Circulation. 2011 Mar 1;123(8):858-65
pubmed: 21321150
Neurology. 2020 Mar 3;94(9):e950-e960
pubmed: 31888969
Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:106-9
pubmed: 23365843
J Neurosci. 2012 Nov 14;32(46):16233-42
pubmed: 23152607
Alzheimers Dement. 2017 Aug;13(8):885-892
pubmed: 28222302
Neurology. 2020 Dec 8;95(23):e3093-e3103
pubmed: 32989109
Neuroimage. 2009 Jul 1;46(3):726-38
pubmed: 19245840
J Alzheimers Dis. 2018;66(3):1095-1104
pubmed: 30400099
J Neuroimaging. 2011 Apr;21(2):e78-82
pubmed: 19888930
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
J Alzheimers Dis. 2017;57(1):293-303
pubmed: 28222518
Acta Neuropathol. 2021 Dec;142(6):937-950
pubmed: 34608542
Curr Alzheimer Res. 2014;11(8):773-84
pubmed: 25212916
Nat Rev Neurosci. 2011 Nov 03;12(12):723-38
pubmed: 22048062
J Cereb Blood Flow Metab. 2018 Jan;38(1):103-115
pubmed: 28151041
Neurology. 2022 Oct 11;99(15):e1640-e1650
pubmed: 36216518
Neurology. 2013 Sep 10;81(11):977-83
pubmed: 23935177
Nature. 2022 Mar;603(7903):885-892
pubmed: 35165441
Sci Rep. 2016 Feb 09;6:20709
pubmed: 26856756
J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):742-6
pubmed: 12023417
JAMA. 2017 Apr 11;317(14):1443-1450
pubmed: 28399252
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
Neurobiol Aging. 2019 Dec;84:225-234
pubmed: 31500909
Biochim Biophys Acta. 2012 Mar;1822(3):361-9
pubmed: 21889590
Nat Commun. 2020 Sep 18;11(1):4727
pubmed: 32948752
Neuroimage. 2018 Apr 15;170:174-181
pubmed: 28315460
Alzheimers Res Ther. 2020 Aug 15;12(1):97
pubmed: 32799929
Nat Rev Neurosci. 2020 Jan;21(1):21-35
pubmed: 31780819
Nat Rev Neurol. 2020 Jan;16(1):30-42
pubmed: 31827267
Alzheimers Dement. 2012 Oct;8(5 Suppl):S71-7
pubmed: 23021624
Alzheimers Res Ther. 2020 Oct 2;12(1):123
pubmed: 33008460
Neurology. 2006 Dec 26;67(12):2192-8
pubmed: 17190943
Neurology. 2022 Sep 19;:
pubmed: 36123127
Ann Clin Transl Neurol. 2020 Aug;7(8):1307-1317
pubmed: 32856790
Neuroimage. 2016 Jul 1;134:658-670
pubmed: 27095307
J Comput Assist Tomogr. 2001 Sep-Oct;25(5):805-16
pubmed: 11584245
Neurobiol Aging. 2018 Aug;68:18-25
pubmed: 29702372
Alzheimers Dement. 2015 Dec;11(12):1510-1519
pubmed: 26079417
J Cereb Blood Flow Metab. 2016 Mar;36(3):621-8
pubmed: 26661151
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
BMC Med. 2014 Nov 11;12:206
pubmed: 25385447
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Acta Neuropathol. 2022 Mar;143(3):349-362
pubmed: 35044500
Neurobiol Aging. 2020 Feb;86:16-26
pubmed: 31718927
J Cereb Blood Flow Metab. 2021 May;41(5):1162-1174
pubmed: 32955960
PLoS One. 2018 May 9;13(5):e0195838
pubmed: 29742105
Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:5319-22
pubmed: 23367130
Ann Neurol. 2021 Aug;90(2):227-238
pubmed: 34041783
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Ann Neurol. 2014 Dec;76(6):845-61
pubmed: 25204284
Alzheimers Dement. 2023 Feb;19(2):569-577
pubmed: 35791732

Auteurs

Princess Newton (P)

Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USA.

Jonathan Tchounguen (J)

Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USA.

Corinne Pettigrew (C)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Chantelle Lim (C)

Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

Zixuan Lin (Z)

Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

Hanzhang Lu (H)

Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

Abhay Moghekar (A)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Marilyn Albert (M)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Anja Soldan (A)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH